Medidata, a Dassault Systèmes company, and Tigermed, a global clinical research provider, extended their 13-year partnership. This renewed collaboration focuses on utilizing the Medidata Platform to enhance clinical trial efficiency, from early phases through post-market surveillance, and speed up the delivery of new therapies globally. The partnership aims to optimize study workflows, ensure regulatory compliance, and improve access to new treatments.
This continued collaboration is noteworthy because it reflects a growing trend in the life sciences industry – the increasing reliance on technology and data-driven solutions to optimize clinical trials. The integration of platforms like Medidata’s with the operational expertise of CROs like Tigermed offers a potentially powerful synergy. Streamlining workflows, automating data capture, and reducing reliance on traditionally labor-intensive processes can significantly impact the speed and cost of bringing new therapies to market, particularly in emerging markets. This is crucial for both pharmaceutical companies seeking to accelerate drug development and patients awaiting innovative treatments.
Tigermed has already completed over 300 clinical studies using the Medidata platform across various therapeutic areas, including oncology, vaccines, and cardiovascular conditions. The expanded partnership will leverage Medidata’s technology, including AI capabilities, further automating data capture and integration across the entire study lifecycle. This will also enhance trial efficiency by better connecting patients, sites, and sponsors.
This partnership signals a continued push towards more efficient and technologically driven clinical trials. The combination of Medidata’s platform and Tigermed’s operational expertise could set a new standard for how trials are conducted, ultimately accelerating the development and availability of new treatments for patients worldwide. The incorporation of AI and further platform integration may also lead to more personalized and effective therapies in the future.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
